Drug intelligence / Profile preview

HL06

Development stage: Unknown
Lead developer: Hualan Genetic Engineering
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HL06 is a recombinant human monoclonal antibody developed by Hualan Genetic Engineering as a biosimilar to ipilimumab (Yervoy). It functions as an immune checkpoint inhibitor by targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of T-cells. By blocking the interaction between CTLA-4 and its ligands (CD80 and CD86) on antigen-presenting cells, HL06 prevents the downregulation of T-cell activity, thereby enhancing the body's immune response against malignant cells. The drug is primarily investigated for the treatment of advanced or metastatic melanoma and is administered via intravenous injection.

Other names: ipilimumab biosimilarrecombinant human anti-CTLA-4 monoclonal antibody

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on HL06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL06.

Explore the full profile